Allogeneic hematopoietic cell transplantation outcomes in patients with Richter’s transformation
Haesook T. Kim(Dana-Farber Cancer Institute), Jennifer R. Brown(Dana-Farber Cancer Institute), Corey Cutler(Harvard University), John Koreth(Otsuka (Japan)), Vincent T. Ho(Dana-Farber Cancer Institute), Mahasweta Gooptu(Harvard University), Erin M. Parry(Broad Institute), Catherine J. Wu(Dana-Farber Cancer Institute), Joseph H. Antin(Dana-Farber Cancer Institute), Rizwan Romee(Washington University in St. Louis), Matthew S. Davids(Dana-Farber Cancer Institute), Robert J. Soiffer(Dana-Farber Cancer Institute), Edwin P. Alyea(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Sarah Nikiforow(Otsuka (Japan)), Peter O. Baker(University of Minnesota Medical Center), Jerome Ritz(Dana-Farber Cancer Institute)
Cited by 24
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k